Flumazenil

CHEMBL407 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
303.3 g/mol
LogP
1.0
Phase
4

This medication acts as a reversal agent for benzodiazepine sedatives by competing with them at the same receptor sites in the brain, rapidly restoring consciousness and breathing. It is used in emergency settings to reverse excessive sedation or overdose from benzodiazepine medications.

分子量

303.2900 g/mol

LogP

1.00

TPSA

64.40 Ų

リピンスキーの五則

適合

治療領域

作用機序

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2

InChI

InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3

Molecular Formula

C15H14FN3O3

HBD / HBA

- / 5

回転可能結合数

3

重原子数

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This medication acts as a reversal agent for benzodiazepine sedatives by competing with them at the same receptor sites in the brain, rapidly restoring consciousness and breathing. It is used in emergency settings to reverse excessive sedation or overdose from benzodiazepine medications.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Flumazenil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL407. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3373. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.